Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

NCT03125200 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Safety

Conditions

Breast Cancer
Non Small Cell Lung Cancer
GastroEsophageal Cancer
Bladder Cancer

Interventions

DRUG: ADCT-502

Sponsor

ADC Therapeutics S.A.